Stifel Financial Corp Increases Stake in Repare Therapeutics Inc. (NASDAQ:RPTX)

Stifel Financial Corp raised its holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) by 36.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 51,700 shares of the company’s stock after buying an additional 13,800 shares during the period. Stifel Financial Corp’s holdings in Repare Therapeutics were worth $178,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of RPTX. Vontobel Holding Ltd. raised its stake in shares of Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after acquiring an additional 4,000 shares in the last quarter. XTX Topco Ltd purchased a new stake in Repare Therapeutics during the 2nd quarter worth about $110,000. Exchange Traded Concepts LLC raised its position in Repare Therapeutics by 21.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after purchasing an additional 8,809 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Repare Therapeutics in the 2nd quarter valued at about $273,000. Finally, Bank of Montreal Can boosted its stake in shares of Repare Therapeutics by 5.4% in the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock valued at $366,000 after buying an additional 5,673 shares during the period. Institutional investors and hedge funds own 85.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Lifesci Capital reaffirmed a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Repare Therapeutics in a report on Friday, November 8th. Finally, Stifel Nicolaus lowered their target price on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 13th.

Repare Therapeutics Stock Performance

Shares of NASDAQ RPTX opened at $1.25 on Tuesday. The stock’s 50-day simple moving average is $2.90 and its 200-day simple moving average is $3.19. The firm has a market capitalization of $53.14 million, a PE ratio of -0.63 and a beta of 0.71. Repare Therapeutics Inc. has a fifty-two week low of $1.20 and a fifty-two week high of $8.49.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.